NewEdge Advisors’s Invesco Pharmaceuticals ETF PJP Stock Holding History

NewEdge Advisors’s Portfolio PJP Stock Details PJP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22.3K	Hold	215	–	–	﹤0.01%	3165
2025 Q4	$22.5K	Buy	+215	New	+$21.6K	﹤0.01%	3222
2023 Q3	–	Sell	-69	Closed	-$5.22K	–	3607
2023 Q2	$5.22K	Hold	69	–	–	﹤0.01%	2799
2023 Q1	$5.24K	Sell	69 -862	-93%	-$66.5K	﹤0.01%	2757
2022 Q4	$54.2K	Buy	+931	New	+$71.6K	﹤0.01%	1680
2017 Q3	–	Sell	-172	Closed	-$10.8K	–	915
2017 Q2	$10.8K	Buy	+172	New	+$10.3K	﹤0.01%	939

Other funds holding PJP

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

PAM

Peak Asset Management Louisville, Colorado $567M AUM 16.44% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Cavalier Investments Alpharetta, Georgia $3.7B AUM 51.42% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

NewEdge Advisors's PJP Position: Q1 2026 in Review

NewEdge Advisors held its Invesco Pharmaceuticals ETF (PJP) position steady in Q1 2026 at 215 shares worth $22.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3165.

NewEdge Advisors first reported a position in PJP in Q2 2017 and has held it in 6 quarters since. The position peaked at $54.2K in Q4 2022. 119 funds tracked by Wall St. Rank hold PJP as of Q1 2026.

NewEdge Advisors held 215 shares of Invesco Pharmaceuticals ETF worth $22.3K as of Q1 2026.
NewEdge Advisors left its Invesco Pharmaceuticals ETF share count unchanged in Q1 2026.
Invesco Pharmaceuticals ETF made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3165 holding.
NewEdge Advisors first reported a position in Invesco Pharmaceuticals ETF in Q2 2017 and has held it in 6 quarters since.
NewEdge Advisors's Invesco Pharmaceuticals ETF position peaked at $54.2K in Q4 2022.
119 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.